• Illuminating Diagnostics

For Payers

We are a full-service, specialty laboratory and integrated technology platform designed to illuminate patient insight, streamline ordering and optimize practice performance.

Luminus Diagnostics commitment to excellence, devoted to delivering the highest quality of service to our providers and their patients extends to Federal and Commercial Payors. Our technology platform ensures the medical necessity of testing performed by our clients resulting in complete accurate information for payers to execute claims on. This results in efficiencies for payers to process claims with required information, decreasing payer cost.

We use both Enzyme Immunoassay (EIA) for screening and highly sensitive Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry (UPLC/MS/MS) for confirmation of results to provide the most accurate testing available.



Luminus uses both Enzyme Immunoassay (EIA)  and highly sensitive Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry for medication monitoring and  confirmation of results.


Luminus provides convenient and responsive clinical diagnostic lab services to physicians’ offices, in-office phlebotomies and patients residing at nursing homes, assisted living facilities, group homes and independent living facilities, as well as other healthcare centers.


Pharmacogenetics is the study of how genes affect a person’s response to drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person’s genetic makeup.

Hereditary Cancer

Luminus genetic tests screen a number of known genes related to hereditary cancers. The goal of every test is to determine a patient’s risk of cancer. This knowledge can help your physician to develop the appropriate or preventative treatment plan for early detection.

Carrier Screening

With Carrier DNA, patients can gain knowledge on their risks of passing inheritable genetic diseases to their children or future children. A more comprehensive assessment can be obtained if both parents are tested.